Stratec SE
Stratec SE, together with its subsidiaries, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. The company designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. It also provides consumables for diagnostics and medical applications; and integrating instrumentation… Read more
Stratec SE (STSEY) - Total Liabilities
Latest total liabilities as of September 2025: $191.16 Million USD
Based on the latest financial reports, Stratec SE (STSEY) has total liabilities worth $191.16 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Stratec SE - Total Liabilities Trend (2002–2024)
This chart illustrates how Stratec SE's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Stratec SE Competitors by Total Liabilities
The table below lists competitors of Stratec SE ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gevelot
PA:ALGEV
|
France | €54.03 Million |
|
Precise Corporation Public Company Limited
BK:PCC
|
Thailand | ฿1.72 Billion |
|
Oncopeptides AB (publ)
PINK:ONPPF
|
USA | $179.25 Million |
|
AudioEye Inc
NASDAQ:AEYE
|
USA | $27.43 Million |
|
Prevas AB Series B
LSE:0H2J
|
UK | Skr350.49 Million |
|
209640
KQ:209640
|
Korea | ₩37.44 Billion |
|
Jagran Prakashan Limited
NSE:JAGRAN
|
India | ₹7.41 Billion |
Liability Composition Analysis (2002–2024)
This chart breaks down Stratec SE's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.80 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Stratec SE's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Stratec SE (2002–2024)
The table below shows the annual total liabilities of Stratec SE from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $202.53 Million | -13.17% |
| 2023-12-31 | $233.25 Million | +35.36% |
| 2022-12-31 | $172.32 Million | +5.87% |
| 2021-12-31 | $162.77 Million | +2.14% |
| 2020-12-31 | $159.36 Million | +13.50% |
| 2019-12-31 | $140.41 Million | +14.08% |
| 2018-12-31 | $123.08 Million | +16.18% |
| 2017-12-31 | $105.94 Million | -7.27% |
| 2016-12-31 | $114.25 Million | +298.65% |
| 2015-12-31 | $28.66 Million | +11.53% |
| 2014-12-31 | $25.70 Million | +24.69% |
| 2013-12-31 | $20.61 Million | -30.97% |
| 2012-12-31 | $29.85 Million | +7.52% |
| 2011-12-31 | $27.77 Million | +3.00% |
| 2010-12-31 | $26.96 Million | +1.73% |
| 2009-12-31 | $26.50 Million | +32.07% |
| 2008-12-31 | $20.06 Million | +9.67% |
| 2007-12-31 | $18.29 Million | +7.70% |
| 2006-12-31 | $16.99 Million | +40.33% |
| 2005-12-31 | $12.10 Million | +19.05% |
| 2004-12-31 | $10.17 Million | -6.63% |
| 2003-12-31 | $10.89 Million | +106174.34% |
| 2002-12-31 | $10.25K | -- |